Head-To-Head Analysis: Zepp Health (NYSE:ZEPP) versus Biotricity (OTCMKTS:BTCY)

Zepp Health (NYSE:ZEPP) and Biotricity (OTCMKTS:BTCY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Volatility and Risk

Zepp Health has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, Biotricity has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500.

Profitability

This table compares Zepp Health and Biotricity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zepp Health	-28.28%	-21.45%	-9.20%
Biotricity	-30.02%	N/A	-75.50%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Zepp Health and Biotricity, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zepp Health	1	0	1	0	2.00
Biotricity	0	0	0	0	0.00

Zepp Health currently has a consensus target price of $64.37, suggesting a potential upside of 130.92%. Given Zepp Health’s stronger consensus rating and higher possible upside, equities analysts plainly believe Zepp Health is more favorable than Biotricity.

Earnings & Valuation

This table compares Zepp Health and Biotricity”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zepp Health	$182.60 million	2.21	-$75.73 million	($4.11)	-6.78
Biotricity	$13.79 million	0.56	-$8.42 million	($0.17)	-1.62

Biotricity has lower revenue, but higher earnings than Zepp Health. Zepp Health is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

52.6% of Zepp Health shares are owned by institutional investors. Comparatively, 3.9% of Biotricity shares are owned by institutional investors. 36.0% of Zepp Health shares are owned by insiders. Comparatively, 10.1% of Biotricity shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Zepp Health beats Biotricity on 10 of the 14 factors compared between the two stocks.

About Zepp Health

Zepp Health Corporation operates as a smart wearable and health technology company worldwide. The company operates in two segments: Self-Branded Products and Others, and Xiaomi Wearable Products. It empowers users to live lives by optimizing health, fitness, and wellness journeys through its consumer brands, Amazfit, Zepp Clarity, and Zepp Aura. The company through its proprietary Zepp Digital Management Platform, which includes the Zepp OS, AI chips, biometric sensors, and data algorithms, delivers cloud-based 24/7 actionable insights and guidance to help users attain wellness goals. The company offers smart bands, watches, modules, and scales; and associated accessories, smart hearable products, sportswear, home fitness equipment, home appliances, and smart watch accessories. It also provides charts and graphs to display analysis of the activity and biometric data collected from users through its Zepp Life and Zepp mobile apps. It offers its products under the Amazfit and Zepp brand names in approximately 90 countries. The company was formerly known as Huami Corporation and changed its name to Zepp Health Corporation in February 2021. Zepp Health Corporation was founded in 2013 and is headquartered in Hefei, the People's Republic of China.

About Biotricity

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.